CAT-4001

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCAT-4001
Drug Alias NameCAT-4000 seriesNRF2 pathway modulator (Catabasis)CAT-4001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitorsNuclear factor erythroid 2-related factor 2 stimulants
TargetsNuclear factor NF-kappa-B complexNuclear factor erythroid 2-related factor 2
Therapy Area/IndicationsInflammationPsoriasisKidney Failure, Chronic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstria Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstria Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsInflammationPsoriasisKidney Failure, Chronic +[6] 

Other Information

ATC CodeN/A
Related LinksN/A